Westmead Hospital Research Provides Significant Data Supporting the Ablation Effectiveness of Stereotaxis Magnetic Navigation

ST. LOUIS, Aug. 27, 2015  -- Stereotaxis, Inc. (STXS) and Westmead Hospital in Australia today announced findings of a recent study comparing the stability of a Niobe(R) remote magnetic navigation system catheter group and a manually controlled catheter group in a validated cardiac wall motion simulator.

"The Niobe system has long demonstrated an enhanced safety profile in comparison to conventional ablations, but its efficacy with lesion creation in highly mobile cardiac regions has not been adequately studied," said Pramesh Kovoor, M.D., Ph.D., Director of Cardiac Services at Westmead Hospital and Associate Professor at the University of Sydney. "We were pleasantly surprised with the results of our research, which provided strong evidence of faster, deeper lesion formation utilizing the Niobe system, due to constant catheter contact in the presence of simulated heart wall motion. As a practitioner, this translates into the potential for more precise, effective ablations in unstable regions of the heart, which could lead to improved patient outcomes and shorter procedure times."

Accuray Awarded Multi-System Order by 21st Century Oncology

SUNNYVALE, Calif., Aug. 21, 2015  -- Accuray Incorporated (ARAY) announced today it has received a multi-system order from 21^st Century Oncology for one CyberKnife^® M6™ and four TomoHDA™ Systems. These are the latest generation CyberKnife and TomoTherapy Systems, and are used worldwide to provide extremely precise radiation treatments for cancerous and non-cancerous tumors throughout the body. The TomoTherapy Systems will replace conventional linear accelerators in single vault freestanding centers, reinforcing the TomoTherapy's value as a mainstream radiation therapy device. Accuray booked the order in its first fiscal quarter of 2016.

"This latest transaction by 21^st Century is the most recent example of a multiple unit order for Accuray systems," said Joshua H. Levine, president and chief executive officer of Accuray. "Whether clinicians choose to order both the CyberKnife and TomoTherapy Systems or multiple units of a single system, we believe these orders speak to the high degree of flexibility and precision our systems provide and growing market interest in our customer-driven solutions."

Inogen Announces Second Quarter 2015 Financial Results

- Record Q2 2015 Total Revenue, Adjusted EBITDA and Net Income --
- Strong Q2 2015 Revenue Growth of 44.9% Over the Same Period in 2014 -
- Raises 2015 Guidance -

GOLETA, Calif., Aug. 11, 2015 -- Inogen, Inc. (INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today reported financial results for the three months ended June 30, 2015.

Second Quarter 2015 Highlights

• Total revenue of $44.0 million, up 44.9% over the same period in 2014.
  • Sales revenue of $32.4 million, up 58.3% over the same period in 2014.
  • Rental revenue of $11.6 million, up 17.3% over the same period in 2014.

    Published: 12 August 2015

    Written by Editor

    Nasdaq   Financial Results   Up on News  

    Read more: Inogen Inc ( INGN )

Echo Therapeutics' Non-Invasive Continuous Glucose Monitoring System Likely Designation as a Class 2 Medical Device in China

ISELIN, N.J., Aug. 12, 2015 -- Echo Therapeutics, Inc. (ECTE), a medical device company focused on non-invasive continuous glucose monitoring (CGM) and associated technologies, today announced that, after numerous consultations with the Chinese government, its strategic partner, Medical Technologies Innovation Asia (MTIA), Ltd., believes that Echo's locally produced needle-free CGM products will be designated as a Class 2 medical device. Class 2 medical devices have a review period of 90 working days after filing submission with the Medical Device Evaluation Center of the China Food and Drug Administration (CFDA).  A formal and final designation from the CFDA is determined only at the time of submission.